This trial is evaluating whether Treatment will improve 1 primary outcome and 14 secondary outcomes in patients with High Risk Pregnancies. Measurement will happen over the course of one-time score at 4-6 weeks postpartum.
This trial requires 90 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are not being studied for commercial purposes.
This case illustrates a successful management of recurrent high risk pregnancy and illustrates why it is important to have a close multidisciplinary, supportive care and rehabilitation pathway in place when managing this vulnerable group.
Risk factors and causes of high risk pregnancies vary considerably between countries and regions of the world. Identifying the individual risk factors in various high risk groups in different regions and countries of the world will help in reducing the high risk pregnancies not only in high risk groups but also in the general population.
High risk pregnancies are characterized by signs of increased nuchal translucency and increased blood pressure. High risk pregnancies are also associated with signs of maternal and fetal hypoxia.
The most common complication is pre-eclampsia and eclampsia occurring in 15%–50% of pregnancies after high-risk pregnancies. High risk pregnancies are defined as those with multiple risk factors. High risk pregnancies are those with factors associated with increased severity and complications of preterm labour. Some risk factors are known and others are unknown. These include nulliparous and pre-eclamptic mothers, gestational diabetes and older maternal age (> 35 years). The risks of perinatal mortality and morbidity are increased with these and other factors. High risk pregnancies are of interest to parents and clinicians in terms of their impact on the lives of their families and children.
While it is commonly recommended during prenatal care that fetuses be screened for Down syndrome once a woman is found to be expecting a child, there is no conclusive evidence to suggest that women should be screened once they are found to be pregnant. Low-risk fetuses may be screened to determine pregnancy termination.
Incomplete treatment is the major contributor to adverse neurodevelopmental outcomes in RDS. The need to improve treatment algorithms and define treatment targets has to receive more attention in order to improve the neurodevelopmental outcomes of these children.
[We find no evidence to support the popular perception that women with risk factors present a higher or a higher risk for delivering babies with major defects than the average. It is possible that the observed trend in these populations may reflect changes in the health-care system. We hypothesize, instead, that more rigorous and comprehensive screening is necessary before birth!
There has been no randomized controlled trial testing the effectiveness of other treatment modalities compared with placebo in patients with advanced cancer. However, a few retrospective observational studies have suggested a benefit to the use of palliative treatment modalities, namely chemotherapy and photodynamic therapy, in advanced HCC in selected patients. In addition, there are a few open, uncontrolled or uncontrolled studies that demonstrate that some treatments for HCC, including chemotherapy and tyrosine kinase inhibitors, may be beneficial to patients with HCC. Clinical trials are urgently needed to confirm these preliminary data.
Pregnancies with pregravid women and women aged 34 or older should receive the full scope of prenatal care and treatment, including a timely recognition of pre- eclampsia and timely delivery to a specialty hospital.
There is no clear evidence that standard care is used in combination with other treatments. However, given this the possible adverse consequences of combined care, and high quality-of-life data from patients from all treatment groups suggests possible combinations that are better than one component treatment alone.
Compared with a placebo, treatment given to high-risk pregnant women with a history of GDM is associated with less risk for subsequent development of T2D, higher risk for development of pre-eclampsia, lower risk for macrosomia, and higher risk for gestational diabetes mellitus. However, in the long term, it is not yet possible to draw definite conclusions regarding the best treatment approach for pregnant women presenting with a history of GDM. For example, treatment with metformin was not associated with increased risk of subsequent development of pre-eclampsia or macrosomia. More research is needed in this area before definitive recommendations can be made.